Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study.
Age
Antibody responses
COVID-19 vaccination
Comorbidity
Frailty
Lifestyle deficits
Journal
Immunity & ageing : I & A
ISSN: 1742-4933
Titre abrégé: Immun Ageing
Pays: England
ID NLM: 101235427
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
18
08
2023
accepted:
13
10
2023
medline:
26
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Immune responses to vaccination vary widely between individuals. The aim of this study was to identify health-related variables potentially underlying the antibody responses to SARS-CoV-2 vaccination in older persons. We recruited participants in the long-running Doetinchem Cohort Study (DCS) who underwent vaccination as part of the national COVID-19 program, and measured antibody concentrations to SARS-CoV-2 Spike protein (S1) and Nucleoprotein (N) at baseline (T0), and a month after both the first vaccination (T1), and the second vaccination (T2). Associations between the antibody concentrations and demographic variables, including age, sex, socio-economic status (SES), comorbidities (cardiovascular diseases and immune mediated diseases), various health parameters (cardiometabolic markers, inflammation markers, kidney- and lung function) and a composite measure of frailty ('frailty index', ranging from 0 to 1) were tested using multivariate models. We included 1457 persons aged 50 to 92 years old. Of these persons 1257 were infection naïve after their primary vaccination series. The majority (N = 954) of these individuals were vaccinated with two doses of BNT162b2 (Pfizer) and their data were used for further analysis. A higher frailty index was associated with lower anti-S1 antibody responses at T1 and T2 for both men (R Components of frailty play a key role in the primary vaccination response to the BNT162b2 vaccine within an ageing population. Older persons with various comorbidities have a lowered immune response after their first vaccination, and while frail and sick older persons see a stronger increase after their second vaccination compared to healthy people, they still have a lower antibody response after their second vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
Immune responses to vaccination vary widely between individuals. The aim of this study was to identify health-related variables potentially underlying the antibody responses to SARS-CoV-2 vaccination in older persons. We recruited participants in the long-running Doetinchem Cohort Study (DCS) who underwent vaccination as part of the national COVID-19 program, and measured antibody concentrations to SARS-CoV-2 Spike protein (S1) and Nucleoprotein (N) at baseline (T0), and a month after both the first vaccination (T1), and the second vaccination (T2). Associations between the antibody concentrations and demographic variables, including age, sex, socio-economic status (SES), comorbidities (cardiovascular diseases and immune mediated diseases), various health parameters (cardiometabolic markers, inflammation markers, kidney- and lung function) and a composite measure of frailty ('frailty index', ranging from 0 to 1) were tested using multivariate models.
RESULTS
RESULTS
We included 1457 persons aged 50 to 92 years old. Of these persons 1257 were infection naïve after their primary vaccination series. The majority (N = 954) of these individuals were vaccinated with two doses of BNT162b2 (Pfizer) and their data were used for further analysis. A higher frailty index was associated with lower anti-S1 antibody responses at T1 and T2 for both men (R
CONCLUSIONS
CONCLUSIONS
Components of frailty play a key role in the primary vaccination response to the BNT162b2 vaccine within an ageing population. Older persons with various comorbidities have a lowered immune response after their first vaccination, and while frail and sick older persons see a stronger increase after their second vaccination compared to healthy people, they still have a lower antibody response after their second vaccination.
Identifiants
pubmed: 37880758
doi: 10.1186/s12979-023-00382-4
pii: 10.1186/s12979-023-00382-4
pmc: PMC10599057
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing covid-19 vaccines for their characteristics, efficacy and effectiveness against SARS-COV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21.
doi: 10.1016/j.cmi.2021.10.005
pubmed: 34715347
Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205.
doi: 10.1016/j.arr.2020.101205
pubmed: 33137510
Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6(12):e006434.
doi: 10.1136/bmjgh-2021-006434
pubmed: 34916273
Jaul E, Barron J. Characterizing the heterogeneity of aging: a vision for a staging system for aging. Front Public Health. 2021;9:513557.
doi: 10.3389/fpubh.2021.513557
pubmed: 34712633
pmcid: 8545798
Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2018;36(36):5350–7.
doi: 10.1016/j.vaccine.2017.07.062
pubmed: 28774561
Collier DA, Ferreira IA, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-COV-2 vaccine BNT162b2. Nature. 2021;596(7872):417–22.
doi: 10.1038/s41586-021-03739-1
pubmed: 34192737
pmcid: 8373615
Wang Y, Dong C, Han Y, Gu Z, Sun C. Immunosenescence, aging and successful aging. Front Immunol. 2022;13:942796.
doi: 10.3389/fimmu.2022.942796
pubmed: 35983061
pmcid: 9379926
van den Hoogen LL, Boer M, Postema A, de Rond L, de Zeeuw-Brouwer ML, Pronk I, et al. Reduced antibody acquisition with increasing age following vaccination with BNT162b2: results from two longitudinal cohort studies in the Netherlands. Vaccines. 2022;10(9):1480.
doi: 10.3390/vaccines10091480
pubmed: 36146557
pmcid: 9504637
Veronese N, Petrovic M, Benetos A, Denkinger M, Gudmundsson A, Knol W, et al. Underrepresentation of older adults in clinical trials on COVID-19 vaccines: a systematic review. Ageing Res Rev. 2021;71:101455.
doi: 10.1016/j.arr.2021.101455
pubmed: 34487916
pmcid: 8413602
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AE, van Doesum JA, van Binnendijk RS, et al. Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for covid-19. JAMA Oncol. 2022;8(10):1477. https://doi.org/10.1001/jamaoncol.2022.3227 .
doi: 10.1001/jamaoncol.2022.3227
pubmed: 35951338
pmcid: 9372904
Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZL, Kummer LY, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):e778-88. https://doi.org/10.1016/s2665-9913(21)00222-8 .
doi: 10.1016/s2665-9913(21)00222-8
pubmed: 34396154
pmcid: 8346242
Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer. 2021;159:259–74.
doi: 10.1016/j.ejca.2021.10.013
pubmed: 34798454
pmcid: 8542448
Caillard S, Thaunat O. Covid-19 vaccination in kidney transplant recipients. Nat Rev Nephrol. 2021;17(12):785–7.
doi: 10.1038/s41581-021-00491-7
pubmed: 34580488
pmcid: 8475856
Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay J-Y, et al. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021;27(8):1319–21.
doi: 10.1038/s41591-021-01435-1
pubmed: 34253930
Witkowski W, Gerlo S, De Smet E, Wejda M, Acar D, Callens S, Heytens S, Padalko E, Vercruysse H, Cools P, Vandekerckhove L. Humoral and cellular responses to COVID-19 vaccination indicate the need for post-vaccination testing in frail population. Vaccines (Basel). 2022;10(2):260. https://doi.org/10.3390/vaccines10020260 .
doi: 10.3390/vaccines10020260
pubmed: 35214717
Vinh DC, Gouin J-P, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, et al. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (uncover): an interim report from a prospective observational cohort study. Lancet Healthy Longev. 2022;3(3):e166–75.
doi: 10.1016/S2666-7568(22)00012-5
pubmed: 35224524
pmcid: 8863504
Semelka CT, DeWitt ME, Callahan KE, Herrington DM, Alexander-Miller MA, Yukich JO, et al. Frailty and COVID-19 mrna vaccine antibody response in the COVID-19 Community Research Partnership. J Gerontol A. 2022;77(7):1366–70.
doi: 10.1093/gerona/glac095
Verschuren W, Blokstra A, Picavet H, Smit H. Cohort profile: the Doetinchem cohort study. Int J Epidemiol. 2008;37(6):1236–41.
doi: 10.1093/ije/dym292
pubmed: 18238821
Picavet HS, Blokstra A, Spijkerman AM, Verschuren WM. Cohort profile update: the Doetinchem Cohort Study 1987–2017: lifestyle, health and chronic diseases in a life course and ageing perspective. Int J Epidemiol. 2017;46(6):1751–1751g. https://doi.org/10.1093/ije/dyx103 .
doi: 10.1093/ije/dyx103
pubmed: 29040549
pmcid: 5837330
Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162B2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999–1009. https://doi.org/10.1016/s2213-2600(21)00220-4 .
doi: 10.1016/s2213-2600(21)00220-4
pubmed: 34224675
pmcid: 8253545
Boroumand AB, Forouhi M, Karimi F, Moghadam AS, Naeini LG, Kokabian P, et al. Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: a systematic review. Front Immunol. 2022;13:940357. https://doi.org/10.3389/fimmu.2022.940357 .
doi: 10.3389/fimmu.2022.940357
pubmed: 36105809
pmcid: 9465310
Trump S, Lukassen S, Anker MS, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. 2021;39:705–16. https://doi.org/10.1038/s41587-020-00796-1 .
doi: 10.1038/s41587-020-00796-1
pubmed: 33361824
Oosthuizen D, Sturrock ED. Exploring the impact of ACE inhibition in immunity and disease. J Renin Angiotensin Aldosterone Syst. 2022;2022:9028969. https://doi.org/10.1155/2022/9028969 .
doi: 10.1155/2022/9028969
pubmed: 36016727
pmcid: 9371878
Duggal NA, Niemiro G, Harridge SD, Simpson RJ, Lord JM. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol. 2019;19(9):563–72. https://doi.org/10.1038/s41577-019-0177-9 .
doi: 10.1038/s41577-019-0177-9
pubmed: 31175337
Batty GD, Deary IJ, Fawns-Ritchie C, Gale CR, Altschul D. Pre-pandemic cognitive function and covid-19 vaccine hesitancy: cohort study. Brain Behav Immun. 2021;96:100–5. https://doi.org/10.1016/j.bbi.2021.05.016 .
doi: 10.1016/j.bbi.2021.05.016
pubmed: 34022372
pmcid: 8133799
den Hartog G, Schepp RM, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N, et al. SARS-COV-2–specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis. 2020;222(9):1452–61. https://doi.org/10.1093/infdis/jiaa479 .
doi: 10.1093/infdis/jiaa479
World Health Organization (WHO). First who international standard for anti-SARS-cov-2 immunoglobulin (human) 2020. Available from: https://www.nibsc.org/documents/ifu/20-136.pdf . Cited 2023 Jul 11.
Vos ER, van Boven M, den Hartog G, Backer JA, Klinkenberg D, van Hagen CC, et al. Associations between measures of social distancing and severe acute respiratory syndrome coronavirus 2 seropositivity: a nationwide population-based study in the Netherlands. Clin Infect Dis. 2021;73(12):2318–21. https://doi.org/10.1093/cid/ciab264 .
doi: 10.1093/cid/ciab264
pubmed: 33772265
pmcid: 8083720
van den Hoogen LL, Smits G, van Hagen CCE, Wong D, Vos ERA, van Boven M, et al. Seropositivity to nucleoprotein to detect mild and asymptomatic SARS-COV-2 infections: a complementary tool to detect breakthrough infections after covid-19 vaccination? Vaccine. 2022;40(15):2251–7. https://doi.org/10.1016/j.vaccine.2022.03.009 .
doi: 10.1016/j.vaccine.2022.03.009
pubmed: 35287986
pmcid: 8904156
Samson LD, Boots AM, Verschuren WMM, Picavet HS, Engelfriet P, Buisman A-M. Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes. Exp Gerontol. 2019;125:110674. https://doi.org/10.1016/j.exger.2019.110674 .
doi: 10.1016/j.exger.2019.110674
pubmed: 31336145
Samson LD, Buisman A, Ferreira JA, Picavet HS, Verschuren WM, Boots AM, et al. Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study. Clin Transl Immunol. 2022;11(2):e1374. https://doi.org/10.1002/cti2.1374 .
doi: 10.1002/cti2.1374